Mallinckrodt’s Bankruptcy Plan Would Cut Payments to Opioid Victims by $1 Billionnews2023-08-23T20:33:07+00:00August 23rd, 2023|The New York Times|
Opioid Settlement Money Is Being Spent on Police Cars and Overtimenews2023-08-15T00:03:26+00:00August 15th, 2023|The New York Times|
Drugmakers Throw ‘Kitchen Sink’ to Halt Medicare Price Negotiationsnews2023-07-23T07:00:18+00:00July 23rd, 2023|The New York Times|
How Gilead Profited by Slow-Walking a Promising H.I.V. Therapynews2023-07-22T18:26:55+00:00July 22nd, 2023|The New York Times|
Merck Sues Over Medicare Drug-Price Negotiation Lawnews2023-06-06T18:41:33+00:00June 6th, 2023|The New York Times|
U.S. Sues to Block Amgen’s $27.8 Billion Takeover of Horizon Therapeuticsnews2023-05-16T18:16:56+00:00May 16th, 2023|The New York Times|
Gilead Wins Key Patent Rights Suit Over HIV Prevention Drug PrEPnews2023-05-09T17:34:57+00:00May 9th, 2023|The New York Times|
Supreme Court Ensures, for Now, Broad Access to Abortion Pillnews2023-04-22T14:39:23+00:00April 22nd, 2023|The New York Times|
Abortion Pill Maker Sues F.D.A. to Protect Drug if a Court Orders It Off the Marketnews2023-04-19T20:30:08+00:00April 19th, 2023|The New York Times|
Supreme Court Could Restrict Abortion Pill Todaynews2023-04-19T13:04:44+00:00April 19th, 2023|The New York Times|